Results 71 to 80 of about 92,873 (239)

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John, Eustace, Alexander J., Mahgoub, Thamir, O'Donovan, Norma, Tryfonopoulos, Dimitrios   +4 more
core  

Targeting WTAP/ROR1/WNT5A‐Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy

Advanced Science, EarlyView.
In hypoxic microenvironment, WNT5A is predominantly secreted by tumor‐associated macrophages. Hypoxia‐induced WTAP mediates ROR1 stability by m6A modifications in a HuR‐dependent manner in Glioma stem cells (GSCs). WNT5A activates the WNT pathway via ROR1 binding on GSCs, driving glioma‐derived endothelial cells (GDECs) differentiation.
Xiaoyong Chen, Bo Pang, Yun Liu, Jiangwei Wang, Lanhui Zheng, Yuzhou Chang, Yingxuan Sun, Haoyuan Sun, Huiyuan Chen, Jiawei Cai, Zanyi Wu, Qing Chang, Yongzhi Wang, Dezhi Kang, Tao Jiang, Ruichao Chai   +15 more
wiley   +1 more source

Current chemotherapy strategies for adults with IDH-wildtype glioblastoma

Frontiers in Oncology
IntroductionGlioblastoma, despite advancements in molecular evolution, remains incurable and has low survival rates. Currently, two of the most commonly used chemotherapy regimens are temozolomide and CCNU.
Jing Bao, Rui Sun, Zhenjiang Pan, Shepeng Wei   +3 more
doaj   +1 more source

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data

Drug Design, Development and Therapy, 2021
Chen Shi,1,2 Xiong Wang,1,2 Changdong Diao,1,2 Haixia Zhu,1,2 Qi Yuan,1,2 Jinmei Liu,1,2 Shijun Li,1,2 Ming Gu,1,2 Yu Zhang1,2 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan,
Shi C, Wang X, Diao C, Zhu H, Yuan Q, Liu J, Li S, Gu M, Zhang Y   +8 more
doaj  

The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial

Trials, 2022
Background Temozolomide is applied as the standard chemotherapy agent in patients with glioblastoma (GBM) after surgery. However, the benefit of this treatment for patients is limited by the invasive growth of gliomas and drug resistance.
Maoyuan Sun, Ning Huang, Yihao Tao, Rong Wen, Guanjian Zhao, Xiang Zhang, Zongyi Xie, Yuan Cheng, Jinning Mao, Guodong Liu   +9 more
doaj   +1 more source

Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis

Advanced Science, EarlyView.
Considering the great challenge in Glioblastoma multiforme (GBM) treatment, the authors designed and synthesized a multifunctional nanoplatform that effectively induced ferroptosis by synergetically inhibiting intrinsic intrisinc anti‐ferroptosis proteins, GPX4 & DHODH, and realized excellent in vitro and in vivo anti‐GBM effect.
Guodong Ren, Xuewei Wang, Panpan Li, Hao Wu, Zhifei Bi, Qi Gao, Bolong Ma, Zixuan Tian, Jianfei Liu, Fuqiang Feng, Wen Liu, Lin Li, Chengwu Zhang   +12 more
wiley   +1 more source

The Synergistic Effects of the Combination of Ciprofloxacin and Temozolomide on Human Glioblastoma A-172 Cell Line

Middle East Journal of Cancer, 2017
Background: Combination therapy has generated remarkable motivation in the clinical setting since it boosts the therapeutic potential of anticancer drugs.
Ashkan Zandi, Taraneh Moini Zanjani, Seyed Ali Ziai, Yalda Khazaei Poul, Mostafa Haji Molla Hoseini   +4 more
doaj  

Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drug

Future Journal of Pharmaceutical Sciences, 2021
Background Crizotinib and Temozolomide are the two major chemotherapy drugs used for the treatment of cancers. Crizotinib is used as a target chemotherapy drug in many cancers. It mainly binds on the ATP binding regions of receptor tyrosine kinases (RTKs)
Saleena Younus, S. S. Vinod Chandra, Achuth Sankar S. Nair   +2 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core